Current status and challenges of antiretroviral research and therapy.
about
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSProgress toward curing HIV infection with hematopoietic cell transplantationA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationStructure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesSynthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease InhibitorsProbing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationSocial, structural and behavioral determinants of overall health status in a cohort of homeless and unstably housed HIV-infected menRecent 5-year Findings and Technological Advances in the Proteomic Study of HIV-associated Disorders.Translational research in behavior analysis: historical traditions and imperative for the futurePharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidineDeterminants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV.HIPdb: a database of experimentally validated HIV inhibiting peptides.Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.Novel enzyme-polymer conjugates for biotechnological applicationsAnalyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Anti-HIV-1 activity, protease inhibition and safety profile of extracts prepared from Rhus parviflora.What determines health-related quality of life among people living with HIV: an updated review of the literature.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa.CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infectionsProgress in the development of new therapies for herpesvirus infectionsNanomedicine as an emerging approach against intracellular pathogensNanotechnology and the treatment of HIV infection.In vitro anti-HIV and antioxidant activity of Hoodia gordonii (Apocynaceae), a commercial plant product.Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCsDesign of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray StudiesPractical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer.Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsClinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev functionBody-drug assemblages: theorizing the experience of side effects in the context of HIV treatment."So far it's been choosing which side effects I want or I can deal with": A grounded theory of HIV treatment side effects among people living with HIV.HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.Total joint arthroplasty in human immunodeficiency virus positive patients.Feline immunodeficiency virus latency.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Chemokine receptor modeling: an interdisciplinary approach to drug design.
P2860
Q26777251-581F31F8-5206-4F73-B1EF-C18F56F14108Q26801269-2F8F4EF1-F07F-424B-8F59-8F6A79153D90Q27319650-2B7A39CE-E0C8-4E16-A53D-FF9D4F05054CQ27665164-97A5CB71-A774-4240-ACFD-A25D50CDE383Q27677537-3F481544-E9B7-46D4-A8A7-2BCD5AB324D1Q27717366-7293A0A9-04FA-4302-B71F-5BB30C0ABE7DQ28482965-3902C3E4-9E68-470E-8A05-7C373F7512C0Q33633451-8F16EDE8-DCC7-4CEC-9E06-52A65F0DC368Q33819517-78990D57-3E84-4261-AA7F-67776D361F98Q33911400-4DEBFC3F-3BEA-448B-9A11-2AACE0A51D7EQ34060532-31D72A32-3F62-4E85-B31C-2B8A37174ECFQ34159738-EC5A3DDE-F28A-41E8-8406-63B809055003Q34538784-1A536FBF-FE45-4CAE-A3BE-79F5244198B8Q34566584-C6C28587-86D3-4984-B692-5A182670F873Q34663350-09FFFA58-9D5A-4C4C-8302-185BCC576843Q34702628-234B6FF0-5A2E-4236-94FF-F1711AD80DEBQ34728884-1C1BC5E7-CDBD-472E-AB7F-7C03269A9EF4Q34995318-CA571F70-4E7F-4B43-8B3A-CE6ED82B6344Q35068416-FEFE7B89-869E-4A08-A420-90F6BFFB3078Q35071617-B53841D3-87E8-478F-87F3-9324A27253B1Q35147717-1BFEBDFE-0E7E-42E0-A9EF-2A9A026F967CQ35270714-58428457-A315-4498-BEE2-B4427E6E14D7Q35590695-1267EC4B-3362-4CAA-95DB-E641F8B38049Q35656908-375D3E00-42A7-422F-93A1-E379435EDFF9Q35943647-5BEE4283-058D-4F14-A694-B2E734B18D3BQ36173448-59B7872F-018C-4D14-B3EE-308AFDD2E168Q36356572-E3ACF699-E46B-4A44-8A7C-BD48050CAB32Q36613697-F82797D5-58AE-4964-B203-6FE87A55DA38Q36727960-31A2082C-ABBB-47AF-89BA-12FF80E93DBAQ37129860-F8585882-A89D-4CEC-A3B1-8998D3F6A142Q37188867-FD904039-9A0C-4696-9916-D14F877236B5Q37255082-A334BACF-7EB9-4F01-8458-A6EF7EE28AC1Q37271140-C6F499A3-63D3-4A51-9966-1A40B87AE649Q37280882-CF3D8176-C1C6-41C2-AC19-B3035ECDDD0DQ37418447-1D5E9465-5E10-4819-A16D-810363A6EBFAQ37771138-F63A8E87-725C-4E14-9620-11CCCAE1794FQ38056449-B0DD6F42-D245-43C8-8C95-D9AC0A3736A1Q38119498-B9FE423D-954A-4412-9B8F-E84AA5FA1490Q38164839-0F3736B8-6784-4413-A6CE-4040728992ABQ38172960-661CC558-826A-4E83-8E31-2784A751EEB4
P2860
Current status and challenges of antiretroviral research and therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status and challenges of antiretroviral research and therapy.
@en
Current status and challenges of antiretroviral research and therapy.
@nl
type
label
Current status and challenges of antiretroviral research and therapy.
@en
Current status and challenges of antiretroviral research and therapy.
@nl
prefLabel
Current status and challenges of antiretroviral research and therapy.
@en
Current status and challenges of antiretroviral research and therapy.
@nl
P1433
P1476
Current status and challenges of antiretroviral research and therapy.
@en
P2093
José A Esté
P356
10.1016/J.ANTIVIRAL.2009.10.007
P50
P577
2009-12-16T00:00:00Z